Neuropilins in Tumor Biology

The neuropilin receptors were first discovered as regulators of nervous system development, acting as semaphorin coreceptors with plexins. Subsequently, the neuropilins were identified as receptors for vascular endothelial growth factor. Since those seminal discoveries, additional ligands that bind neuropilins have been described, and many studies have implicated neuropilins in playing key roles in tumor biology. Recent evidence has shown that manipulating neuropilin function can regulate tumor growth and metastasis through effects on vascular biology in the case of neuropilin-1 and lymphatic biology in the case of neuropilin-2. A direct role for neuropilins within in tumor cells has also been postulated. As data continue to accumulate pointing to a role for neuropilins in cancer, the promise for targeting this pathway is beginning to unfold.

[1]  A. Eichmann,et al.  Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos , 2008, Development.

[2]  P. Frankel,et al.  Neuropilins: structure, function and role in disease. , 2008, The Biochemical journal.

[3]  F. Peale,et al.  Blocking neuropilin-2 function inhibits tumor cell metastasis. , 2008, Cancer cell.

[4]  M. Klagsbrun,et al.  Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis , 2008, Angiogenesis.

[5]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[6]  H. Friess,et al.  Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer , 2007, International journal of cancer.

[7]  M. Klagsbrun,et al.  Targeting endothelial and tumor cells with semaphorins , 2007, Cancer and Metastasis Reviews.

[8]  Jeffery G Herman,et al.  Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. , 2007, International journal of oncology.

[9]  M. Tessier-Lavigne,et al.  Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. , 2007, Journal of molecular biology.

[10]  M. Crépin,et al.  Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.

[11]  G. Neufeld,et al.  Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. , 2006, Blood.

[12]  E. Bruyneel,et al.  Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A–mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts , 2006, Molecular Cancer Therapeutics.

[13]  K. Alitalo,et al.  Functional interaction of VEGF‐C and VEGF‐D with neuropilin receptors , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  G. Mann,et al.  Targeting lymphangiogenesis to prevent tumour metastasis , 2006, British Journal of Cancer.

[15]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[16]  H. Drabkin,et al.  Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. , 2005, Neoplasia.

[17]  M. Devocelle,et al.  A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells , 2005, British Journal of Cancer.

[18]  M. Kreuter,et al.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. , 2004, The Journal of clinical investigation.

[19]  Holger Gerhardt,et al.  Neuropilin‐1 is required for endothelial tip cell guidance in the developing central nervous system , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[20]  B. Eickholt,et al.  Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. , 2003, Cancer research.

[21]  S. Nathanson,et al.  Insights into the mechanisms of lymph node metastasis , 2003, Cancer.

[22]  Bernd Fritzsch,et al.  Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. , 2003, Developmental cell.

[23]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[24]  M. Karkkainen,et al.  Abnormal lymphatic vessel development in neuropilin 2 mutant mice. , 2002, Development.

[25]  C. Tse,et al.  Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. , 2002, Cancer research.

[26]  T. Kitsukawa,et al.  Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Tse,et al.  Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. , 2002, Cancer research.

[28]  J. Minna,et al.  Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[30]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Soker,et al.  Neuropilin‐1 expression by tumor cells promotes tumor angiogenesis and progression , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  S. Soker,et al.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Yagi,et al.  A requirement for neuropilin-1 in embryonic vessel formation. , 1999, Development.

[34]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[35]  M. Tessier-Lavigne,et al.  Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III , 1997, Cell.

[36]  Alex L Kolodkin,et al.  Neuropilin Is a Semaphorin III Receptor , 1997, Cell.

[37]  W. Franklin,et al.  Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. , 1996, Oncogene.

[38]  Franklin Peale,et al.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.

[39]  H. Drabkin,et al.  Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. , 2003, Neoplasia.